SERA
Sera Prognostics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$2.02
+2.02%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
Market Cap
$79.69M
MomentumView details →
1D Return
+2.02%
YTD Return
−31.19%
RSI (14)
48.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
Market Cap
$79.69M
RSI (14)
48.8
MomentumView details →
1D Return
+2.02%
YTD Return
−31.19%
SummaryUpdated Jun 1, 2026
Sera Prognostics, Inc. (NASDAQ:SERA) is a women's health diagnostic company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in July 2021 and focuses on developing blood-based biomarker tests to predict and improve pregnancy outcomes. Sera Prognostics operates in the specialized field of prenatal diagnostics, addressing one of healthcare's most pressing challenges: preterm birth, which affects approximately 1 in 10 babies born in the United States and has seen rates increase by 12% between 2014-2022.
Similar companies
Latest newsMore news →